Test ID: WASEQ Alpha Globin Gene Sequencing, Varies
Useful For
Diagnosing nondeletional alpha thalassemia
Testing for nondeletional alpha thalassemia in a symptomatic individual
Follow-up testing to an abnormal hemoglobin electrophoresis that identified an alpha-globin chain variant
Special Instructions
Method Name
Polymerase Chain Reaction (PCR)/ Sanger Sequencing
Reporting Name
Alpha Globin Gene Sequencing, BSpecimen Type
VariesOrdering Guidance
For first tier testing for alpha thalassemia detection, order THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Serum and Blood.
For first tier testing for an alpha-globin variant, order HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood.
If genetic testing is desired, the first-tier genetic test assesses large deletional alpha-thalassemia alterations. Order AGDD / Alpha Globin Cluster Locus Deletion/Duplication, Varies.
Necessary Information
1. Patient's age is required.
2. Include recent transfusion information.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable:Â Yellow top (ACD), green top (sodium heparin)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in the original tube. Do not aliquot
Specimen Stability Information: Refrigerate 30 days(preferred)/Ambient 14 days
Specimen Type: Extracted DNA from whole blood
Container/Tube: 1.5- to 2-mL tube
Specimen Volume: Entire specimen
Collection Instructions:
1. Label specimen as extracted DNA and source of specimen
2. Provide volume and concentration of the DNA
Specimen Stability Information:Â Frozen (preferred)/Refrigerate/Ambient
Specimen Minimum Volume
Blood: 1 mL
Extracted DNA: 50 mcL at 50 ng/mcL concentration
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Clinical Information
Alpha-globin gene sequencing detects alpha-globin variants and nondeletional alpha-thalassemia variants.
Alpha thalassemia is the most common monogenic condition in the world. It is estimated that up to 5% of the world's population carries at least one alpha-thalassemia variant and, in the United States, approximately 30% of African Americans are thought to carry an alpha-thalassemia variant. Alpha-thalassemia variations are most common in individuals of Southeastern Asian, African, Mediterranean, Indian, and Middle Eastern descent, but they can be found in persons from any ethnic group.
Four alpha-globin genes are normally present, 2 copies on each chromosome 16. Alpha-thalassemia variants result in decreased alpha-globin chain production. In general, alpha thalassemia is characterized by hypochromic, microcytic anemia and varies clinically from asymptomatic (alpha-thalassemia silent carrier and alpha-thalassemia trait) to lethal hemolytic anemia (hemoglobin [Hb] Barts hydrops fetalis).
Large deletions of the alpha-globin genes account for approximately 90% of alpha-thalassemia alterations, and these variations will not be detected by alpha-globin gene sequencing. Other variants, such as point alterations or small deletions within the alpha-globin genes, account for most of the remaining 10% of alpha-thalassemia variations. These nondeletional subtypes can be detected by alpha-globin gene sequencing. The most common nondeletional alpha-thalassemia variant is Hb Constant Spring.
The majority of alpha-globin chain variants are clinically and hematologically benign however, some cause erythrocytosis and chronic hemolytic anemia. Hemoglobin electrophoresis may not be able to confirm their identity. In these instances, alpha-globin gene sequencing can be useful.
Reference Values
An interpretive report will be provided.
Interpretation
An interpretive report will be provided.
Clinical Reference
1. Harteveld CL, Higgs DR: Alpha-thalassemia. Orphanet J Rare Dis. 2010;5:13
2. Hoyer JD, Hoffman DR: The Thalassemia and hemoglobinopathy syndromes. In: McClatchey, KD, ed. Clinical Laboratory Medicine. 2nd ed. Lippincott Williams and Wilkins. 2002;866-895
3. Farashi S, Harteveld CL: Molecular basis of a-thalassemia. Blood Cells Mol Dis. 2018 May;70:43-53. doi: 10.1016/j.bcmd.2017.09.004
4. Henderson SJ, Timbs AT, McCarthy J, et al: Ten years of routine a- and B-globin gene sequencing in UK hemoglobinopathy referrals reveals 60 novel mutations. Hemoglobin. 2016;40(2):75-84. doi: 10.3109/03630269.2015.1113990
Day(s) Performed
Monday through Friday
Report Available
10 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81259-HBA1/HBA2; full sequence
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
WASEQ | Alpha Globin Gene Sequencing, B | 87730-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
61362 | Alpha Globin Gene Sequencing, B | 87730-8 |
43921 | Interpretation | 69047-9 |
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Metabolic Hematology Patient Information (T810)
3. If not ordering electronically, complete, print, and send Benign Hematology Test Request Form (T755) with the specimen
mml-benign-hematology-disorders